Integrated clinical operations, safety, data, and technology supporting complex oncology programs worldwide.
Sitero is an oncology-focused CRO partner for sponsors who need confident execution across complex protocols, global sites, and tight timelines. We combine full-service clinical trial delivery with an integrated technology ecosystem to reduce operational friction and keep studies on track.
Sitero provides comprehensive oncology CRO services supporting complex clinical trials across a range of oncology indications and treatment approaches, including immuno-oncology therapies and colorectal cancer studies, from early-phase development through global trials.
Tech-Enabled Oncology CRO Services for Complex Clinical Trials
Oncology development introduces challenges that generalist operating models struggle to absorb:
Sitero’s model is designed to reduce handoffs across vendors and align operations, safety, and data under one execution approach.
Oncology clinical trials also involve scientific complexities such as biomarker-driven patient selection, evolving standards of care, and multi-arm study designs. These factors require CRO partners who can combine operational execution with deep understanding of oncology trial design and patient populations.
Sitero’s capabilities support innovative oncology trial designs including:
Oncology CRO services for complex clinical trials
Full-service clinical operations
Run your oncology study with consistent ownership from start-up through execution:
Oncology patient recruitment requires close collaboration with experienced investigators and high-performing research sites. Sitero works with oncology-focused clinical sites and academic centers to support efficient study startup, targeted patient recruitment strategies, and sustained site engagement throughout the trial lifecycle.
Biometrics: Data Management and Biostatistics
Support clean, analysis-ready data for complex oncology endpoints:
Many modern oncology trials rely on genomic profiling and biomarker-driven patient selection. Sitero supports precision oncology programs through biomarker data integration, coordination with central laboratories, and management of complex eligibility criteria.
IRB and Committee Operations
Reduce administrative drag and maintain governance:
Drug Safety and Pharmacovigilance Support
Maintain safety visibility and regulatory readiness:
Oncology therapies often involve complex safety monitoring requirements and accelerated regulatory pathways. Sitero supports oncology sponsors with pharmacovigilance programs designed to maintain regulatory readiness while ensuring continuous safety oversight.
Biosafety and IBC Services
Support studies requiring biosafety rigor and coordination:
Clinical Trial Technology that Supports Execution
Sitero’s delivery model is supported by a broad eClinical ecosystem, including:
EDC
RTSM/IRT
eConsent and eCOA
CTMS and eTMF
Payments
Insights and Reporting
This is designed to reduce workflow fragmentation across sponsors, sites, and study teams.
Sitero Key Metrics
Integrated Workflows to Reduce Site Burden
For sponsors seeking simpler site execution, Sitero can align workflows across eConsent, EDC, and RTSM to reduce manual steps and improve coordination.
Global Oncology Trial Experience
Sitero supports oncology studies across a broad international footprint, helping sponsors manage global execution with consistent oversight and deliver across diverse indications, including immuno-oncology therapies and colorectal cancer clinical trials.
Why Sponsors Choose Sitero for Oncology Trials
Sponsors typically select Sitero when they need:
A partner that can cover operational execution plus enabling systems
Clear ownership and predictable delivery for lean sponsor teams
Broad functional capabilities beyond a single product or point solution
Global support without unnecessary complexity
FAQs
Yes. Sitero combines full-service delivery with an integrated eClinical technology ecosystem (EDC, RTSM/IRT, eConsent/eCOA, CTMS/eTMF, payments, and reporting).
Yes. Sitero supports PV and safety operations including case management, aggregate reporting, safety submissions, and signal detection/management.
Yes. Oncology programs with higher protocol complexity benefit from a model that aligns operational execution and oversight from the start.
Look for proven oncology experience, global execution capability, and an operating model that reduces handoffs across clinical operations, safety, governance, and data.
